ArticleBMC complementary medicine and therapies2025
Assessment of cytotoxic, anti-proliferative, anti-metastatic, and morphometric effects of Tecoma stans extracts against MDA-MB-231 human breast cancer cell line.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer remains the most commonly diagnosed cancer type among women, with a high mortality rate due to metastasis. Chemotherapy remains very aggressive, with burdensome side effects on the body. Tecoma stans is an ornamental plant widely used to treat many diseases according to its various pharmacological properties. This study aimed to investigate the cytotoxic, antiproliferative, and antimetastatic activities of Tecoma stans leaves & flowers methanolic extract (TSLME &TSFME) on a highly metastatic MDA-MB-231 breast cancer cell line.
methodsGas chromatography-mass spectrometry (GC-MS) analysis of TSLME and TSFME was carried out to identify present bioactive compounds. TSLME and TSFME were used to assess their cytotoxic (Trypan Blue Exclusion Assay), antiproliferative (MTT Assay), and anti-metastatic activity (Wound Healing Assay) on the triple-negative breast cancer cell line MDA-MB-231, along with their impact on the morphology of metastatic cells.
resultsTSLME showed significantly higher cytotoxicity on MDA-MB-231 cancer cells compared to TSFME at 800 µg/mL. On the contrary, at 200 and 100 µg/mL, TSFME exhibited a more robust antiproliferative effect than TSLME. Additionally, TSLME and TSFME exhibited a significant inhibitory effect on the cell motility upon 24 h at 48 h incubations. Moreover, TSLME and TSFME induced apoptosis in MDA-MB-231 cells and altered their morphology at different concentrations (Decrease in the cell surface area, plasma membrane bleb formation, and nuclear condensation). TSLME and TSFME significantly reduced the cell body and field diameter and process thickness of MDA-MB-231 cells at 800 µg/mL (TSLME > TSFME) and at 200 µg/mL (TSFME > TSLME) which can be an indicator of cell cycle arrest as a response to cellular stress or DNA damage. The pharmacological activities demonstrated in this research by TSLME and TSFME can be attributed to numerous bioactive molecules detected through GC-MS analysis with anticancer activities. These compounds may have acted singularly or synergistically in a concentration-dependent manner.
conclusionThis study revealed the cytotoxic, antiproliferative, and antimetastatic effects of Tecoma stans. Following in-depth in vivo research and clinical trials, Tecoma stans could therefore be used as a promising chemotherapeutic drug against highly metastatic human breast cancer cell lines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.